INDICATION
EMPLICITI® (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

SELECTED IMPORTANT SAFETY INFORMATION
EMPLICITI with lenalidomide and dexamethasone (ERd) or pomalidomide and dexamethasone (EPd) is associated with Warnings and Precautions related to: Infusion Reactions, Infections, Second Primary Malignancies, Hepatotoxicity, Interference with Determination of Complete Response, Pregnancy/Females and Males of Reproductive Potential, and Adverse Reactions.

Please see detailed Important Safety Information throughout.
Click here for full Prescribing Information.
EMPLICITI is administered as a component of the EPd regimen

**EMPLICITI + Pd: DOSING SCHEDULE**

Treatment should continue until disease progression or unacceptable toxicity

**EPd DOSING SCHEDULE**

<table>
<thead>
<tr>
<th>CYCLES 1 &amp; 2 (28 days each)</th>
<th>DOSE EMPLICITI ONCE PER WEEK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DAY</strong></td>
<td>1</td>
</tr>
<tr>
<td>EMPLICITI intravenously</td>
<td>80 mg/kg</td>
</tr>
<tr>
<td>Pomalidomide 4 mg orally</td>
<td>☑</td>
</tr>
<tr>
<td>Dexamethasone (mg) orally*</td>
<td>≤75 years old</td>
</tr>
<tr>
<td>&gt;75 years old</td>
<td>8</td>
</tr>
<tr>
<td>Dexamethasone (mg) intravenously</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CYCLES 3 and onward (28 days each)</th>
<th>DOSE EMPLICITI ONCE EVERY 4 WEEKS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DAY</strong></td>
<td>1</td>
</tr>
<tr>
<td>EMPLICITI intravenously</td>
<td>80 mg/kg</td>
</tr>
<tr>
<td>Pomalidomide 4 mg orally</td>
<td>☑</td>
</tr>
<tr>
<td>Dexamethasone (mg) orally*</td>
<td>≤75 years old</td>
</tr>
<tr>
<td>&gt;75 years old</td>
<td>8</td>
</tr>
<tr>
<td>Dexamethasone (mg) intravenously</td>
<td>8</td>
</tr>
</tbody>
</table>

*Oral dexamethasone should be taken between 3 and 24 hours before EMPLICITI infusion.

**SELECTED IMPORTANT SAFETY INFORMATION**

**Infusion Reactions**
- Infusion reactions were reported in 10% of patients treated with EMPLICITI in the ELOQUENT-2 trial [EMPLICITI + lenalidomide + dexamethasone (ERd) vs lenalidomide + dexamethasone (Rd)] and 3.3% in the ELOQUENT-3 trial [EMPLICITI + pomalidomide + dexamethasone (EPd) vs pomalidomide + dexamethasone (Pd)].
- In the ELOQUENT-2 trial, all infusion reactions were Grade 3 or lower, with Grade 3 infusion reactions occurring in 1% of patients. The most common symptoms included fever, chills, and hypertension. Bradycardia and hypotension also developed during infusions. In the trial, 5% of patients required interruption of the administration of EMPLICITI for a median of 25 minutes due to infusion reactions, and 1% of patients discontinued due to infusion reactions. Of the patients who experienced an infusion reaction, 70% (23/33) had them during the first dose.

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
EMPLICITI + Pd: PREMEDICATION AND INFUSION RATES

Patients must be premedicated before each dose of EMPLICITI

PRETREATMENT ON DAYS THAT EMPLICITI IS ADMINISTERED

<table>
<thead>
<tr>
<th>3–24 hours prior</th>
<th>45–90 minutes prior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral dexamethasone:</td>
<td>8 mg IV dexamethasone</td>
</tr>
<tr>
<td>Patients ≤75 years old: 28 mg</td>
<td>+</td>
</tr>
<tr>
<td>Patients &gt;75 years old: 8 mg</td>
<td>H1 blocker: Diphenhydramine (25–50 mg orally or IV) or equivalent</td>
</tr>
<tr>
<td></td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>H2 blocker</td>
</tr>
<tr>
<td></td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen (650–1000 mg orally)</td>
</tr>
</tbody>
</table>

If no infusion reactions develop, the infusion rate may be increased in a stepwise fashion as shown below:

INFUSION RATE FOR EMPLICITI*

<table>
<thead>
<tr>
<th>EMPLICITI 10 mg/kg intravenously</th>
<th>0</th>
<th>30 min</th>
<th>60 min or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1, Dose 1</td>
<td>0.5 mL/min (30 mL/hr)</td>
<td>1 mL/min (60 mL/hr)</td>
<td>2 mL/min (120 mL/hr)</td>
</tr>
<tr>
<td>Cycle 1, Dose 2</td>
<td>3 mL/min (180 mL/hr)</td>
<td>4 mL/min (240 mL/hr)</td>
<td></td>
</tr>
<tr>
<td>Cycle 1, Dose 3, 4, and Cycle 2</td>
<td>5 mL/min (300 mL/hr)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EMPLICITI 20 mg/kg intravenously</th>
<th>0</th>
<th>30 min or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 3</td>
<td>3 mL/min (180 mL/hr)</td>
<td>4 mL/min (240 mL/hr)</td>
</tr>
<tr>
<td>Cycle 4 onwards</td>
<td>5 mL/min (300 mL/hr)</td>
<td></td>
</tr>
</tbody>
</table>

EMPLICITI should be initiated at 0.5 mL/min. If no infusion reactions develop, the infusion rate may be increased in a stepwise fashion as shown above. Presence and severity of infusion reactions may lengthen the infusion time for EMPLICITI.

*The maximum infusion rate should not exceed 5 mL/min.

SELECTED IMPORTANT SAFETY INFORMATION

Infusion Reactions (cont’d)

- In the ELOQUENT-3 trial, the only infusion reaction symptom was chest discomfort (2%), which was Grade 1. All the patients who experienced an infusion reaction had them during the first treatment cycle.
- If a Grade 2 or higher infusion reaction occurs, interrupt the EMPLICITI infusion and institute appropriate medical and supportive measures. If the infusion reaction recurs, stop the EMPLICITI infusion and do not restart it on that day. Severe infusion reactions may require permanent discontinuation of EMPLICITI therapy and emergency treatment.
- Premedicate with dexamethasone, H1 blocker, H2 blocker, and acetaminophen prior to EMPLICITI infusion.

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
EMPLICITI + Rd: DOSING SCHEDULE

EMPLICITI is administered as a component of the ERd regimen

Treatment should continue until disease progression or unacceptable toxicity

ERd DOSING SCHEDULE

<table>
<thead>
<tr>
<th>CYCLES 1 &amp; 2 (28 days each)</th>
<th>DOSE EMPLICITI ONCE PER WEEK</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAY</td>
<td>1</td>
</tr>
<tr>
<td>EMPLICITI intravenously</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Lenalidomide 25 mg orally</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone (mg) orally*</td>
<td>28</td>
</tr>
<tr>
<td>Dexamethasone (mg) intravenously</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CYCLES 3 and onward (28 days each)</th>
<th>DOSE EMPLICITI ONCE EVERY 2 WEEKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAY</td>
<td>1</td>
</tr>
<tr>
<td>EMPLICITI intravenously</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Lenalidomide 25 mg orally</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone (mg) orally*</td>
<td>28</td>
</tr>
<tr>
<td>Dexamethasone (mg) intravenously</td>
<td>8</td>
</tr>
</tbody>
</table>

*Oral dexamethasone should be taken between 3 and 24 hours before EMPLICITI infusion.

SELECTED IMPORTANT SAFETY INFORMATION

Infections

- In the ELOQUENT-2 trial (N=635), infections were reported in 81% of patients in the ERd arm and 74% in the Rd arm.
- Grade 3-4 infections were 28% (ERd) and 24% (Rd). Discontinuations due to infections were 3.5% (ERd) and 4.1% (Rd). Fatal infections were 2.5% (ERd) and 2.2% (Rd). Opportunistic infections were reported in 22% (ERd) and 13% (Rd). Fungal infections were 10% (ERd) and 5% (Rd).
- Herpes zoster was 14% (ERd) and 7% (Rd).

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
EMPLICITI + Rd: PREMEDICATION AND INFUSION RATES

Patients must be premedicated before each dose of EMPLICITI

PRETREATMENT ON DAYS THAT EMPLICITI IS ADMINISTERED

3–24 hours prior

Oral dexamethasone: 28 mg

45–90 minutes prior

8 mg IV dexamethasone

H₂ blocker: Diphenhydramine (25–50 mg orally or IV) or equivalent

H₁ blocker

Acetaminophen (650–1000 mg orally)

If no infusion reactions develop, the infusion rate may be increased in a stepwise fashion as shown below:

INFUSION RATE FOR EMPLICITI*

<table>
<thead>
<tr>
<th>EMPLICITI 10 mg/kg</th>
<th>0</th>
<th>30 min</th>
<th>60 min or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>intravenously</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cycle 1, Dose 1</td>
<td>0.5 mL/min (30 mL/hr)</td>
<td>1 mL/min (60 mL/hr)</td>
<td>2 mL/min (120 mL/hr)</td>
</tr>
<tr>
<td>Cycle 1, Dose 2</td>
<td>3 mL/min (180 mL/hr)</td>
<td>4 mL/min (240 mL/hr)</td>
<td></td>
</tr>
<tr>
<td>Cycle 1, Dose 3 onwards</td>
<td>5 mL/min (300 mL/hr)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The maximum infusion rate should not exceed 5 mL/min.

SELECTED IMPORTANT SAFETY INFORMATION

Infections (cont’d)

• In the ELOQUENT-3 trial (N=115), infections were reported in 65% of patients in both the EPd arm and the Pd arm. Grade 3-4 infections were reported in 13% (EPd) and 22% (Pd). Discontinuations due to infections were 7% (EPd) and 5% (Pd). Fatal infections were 5% (EPd) and 3.6% (Pd). Opportunistic infections were reported in 10% (EPd) and 9% (Pd). Herpes zoster was reported in 5% (EPd) and 1.8% (Pd).

• Monitor patients for development of infections and treat promptly.

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
Dose delay, interruption, or discontinuation

Infusion reactions were reported in 10% of patients treated with ERd and 3.3% of those treated with EPd. With ERd, all reports of infusion reaction were Grade 3 or lower, and Grade 3 infusion reactions occurred in 1% of patients. With EPd, the only infusion reaction was chest discomfort (2%), which was Grade 1.

If a Grade 2 or higher infusion reaction occurs during EMPLICITI administration:

1. Interrupt the infusion and institute appropriate medical and supportive measures

2. Upon resolution to Grade 1 or lower, restart EMPLICITI at 0.5 mL/min

3. Gradually increase infusion at a rate of 0.5 mL/min every 30 minutes as tolerated to the rate at which the infusion reaction occurred

4. Resume the escalation regimen if there is no recurrence of the infusion reaction

- In patients who experience an infusion reaction, monitor vital signs every 30 minutes for 2 hours after the end of the EMPLICITI infusion. If the infusion reaction recurs, stop the EMPLICITI infusion and do not restart on that day. Severe infusion reactions may require permanent discontinuation of EMPLICITI therapy and emergency treatment
- If the dose of one drug in the regimen is delayed, interrupted, or discontinued, the treatment with the other drugs may continue as scheduled. However, if dexamethasone is delayed or discontinued, the administration of EMPLICITI should be based on clinical judgment (ie, risk of hypersensitivity)
- Dose delay and modification for dexamethasone, pomalidomide, and lenalidomide should be performed as recommended in their Prescribing Information

SELECTED IMPORTANT SAFETY INFORMATION

Second Primary Malignancies

- In the ELOQUENT-2 trial (N=635), invasive second primary malignancies (SPM) were 9% (ERd) and 6% (Rd). The rate of hematologic malignancies was the same between ERd and Rd treatment arms (1.6%). Solid tumors were reported in 3.5% (ERd) and 2.2% (Rd). Skin cancer was reported in 4.4% (ERd) and 2.8% (Rd).
- In the ELOQUENT-3 trial (N=115), invasive SPMs were 0% (EPd) and 1.8% (Pd).
- Monitor patients for the development of SPMs.

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
**FOUR-STEP PREPARATION FOR EMPLICITI INFUSION**

**STEP 1:** Determine vial quantity based on patient weight

Because dosing for EMPLICITI is weight-based, the dose of EMPLICITI will vary by patient, and may be provided through a combination of vial sizes.

### EXAMPLES OF VIAL QUANTITIES NEEDED FOR WEIGHT-BASED DOSING OF EMPLICITI

<table>
<thead>
<tr>
<th>10 mg/kg dose</th>
<th>20 mg/kg dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of vials</strong>*</td>
<td><strong>Total dose (mg)</strong></td>
</tr>
<tr>
<td>200 x2</td>
<td>410–600</td>
</tr>
<tr>
<td>200 + 400</td>
<td>610–700</td>
</tr>
<tr>
<td>400 x2</td>
<td>710–800</td>
</tr>
<tr>
<td>400 x3</td>
<td>810–900</td>
</tr>
<tr>
<td>400 x2 + 400</td>
<td>910–1000</td>
</tr>
<tr>
<td>400 + 400 x2</td>
<td>1010–1100</td>
</tr>
<tr>
<td>400 x3</td>
<td>1110–1200</td>
</tr>
<tr>
<td>400 x3 + 400</td>
<td>1210–1300</td>
</tr>
<tr>
<td>400 x2 + 400 x2</td>
<td>1310–1400</td>
</tr>
</tbody>
</table>

*Depending on the weight-based dose, the full amount in the vials may not be used.

### SELECTED IMPORTANT SAFETY INFORMATION

**Hepatotoxicity**

- In the ELOQUENT-2 trial (N=635), AST/ALT >3X the upper limit, total bilirubin >2X the upper limit, and alkaline phosphatase <2X the upper limit were 2.5% (ERd) vs 0.6% (Rd). Of 8 patients experiencing hepatotoxicity, 2 patients discontinued treatment while 6 patients had resolution and continued. Monitor liver enzymes periodically. Stop EMPLICITI upon ≥Grade 3 elevation of liver enzymes. Continuation of treatment may be considered after return to baseline values.

Please see additional Important Safety Information throughout. [Click here for full Prescribing Information.](#)
FOUR-STEP PREPARATION FOR EMPLICITI INFUSION (cont’d)

**STEP 2:** Determine the volume of SWFI needed for reconstitution

<table>
<thead>
<tr>
<th>Strength</th>
<th>Amount of SWFI, USP required for reconstitution</th>
<th>Deliverable volume of reconstituted EMPLICITI in the vial</th>
<th>Post-reconstitution concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 mg vial</td>
<td>13 mL</td>
<td>12 mL*</td>
<td>25 mg/mL</td>
</tr>
<tr>
<td>300 mg vial</td>
<td>17 mL</td>
<td>16 mL*</td>
<td>25 mg/mL</td>
</tr>
</tbody>
</table>

**STEP 3:** Reconstitute lyophilized powder cake with appropriate volume of SWFI

**Reconstitute**
- Aseptically reconstitute each EMPLICITI vial with a syringe of adequate size and a less than or equal to 18-gauge needle (eg, 17-gauge)
- A slight back pressure may be experienced during administration of the SWFI, which is considered normal

**Mix**
- Hold the vial upright and swirl the solution by rotating the vial to dissolve the lyophilized cake
- Invert the vial a few times in order to dissolve any powder that may be present on top of the vial or the stopper. Avoid vigorous agitation. **DO NOT SHAKE**
- The lyophilized powder should dissolve in less than 10 minutes

**Let stand**
- After the remaining solids are completely dissolved, allow the reconstituted solution to stand for 5 to 10 minutes
- The reconstituted preparation results in a colorless to slightly yellow, clear to slightly opalescent solution
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit
- Discard the solution if any particulate matter or discoloration is observed

*After reconstitution, each vial contains overfill to allow for withdrawal of 12 mL (300 mg) and 16 mL (400 mg), respectively. SWFI=sterile water for injection; USP=United States Pharmacopeia.

**SELECTED IMPORTANT SAFETY INFORMATION**

**Interference with Determination of Complete Response**
- EMPLICITI is a humanized IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and possibly relapse from complete response in patients with IgG kappa myeloma protein.

*Please see additional Important Safety Information throughout. Click here for full Prescribing Information.*
STEP 4: Dilute for infusion

- Once the reconstitution is completed, withdraw the necessary volume for the calculated dose from each vial, up to a maximum of 16 mL from a 400 mg vial and 12 mL from a 300 mg vial.
- Further dilute with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP, into an infusion bag made of polyvinyl chloride or polyolefin. The final infusion concentration should range between 1 mg/mL and 6 mg/mL.
- The volume of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP should be adjusted so as not to exceed 5 mL/kg of patient weight at any given dose of EMPLICITI.

Complete the EMPLICITI infusion within 24 hours of reconstitution of the EMPLICITI lyophilized powder.

SELECTED IMPORTANT SAFETY INFORMATION

Pregnancy/Females and Males of Reproductive Potential
- There are no available data on EMPLICITI use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
- There is a risk of fetal harm, including severe life-threatening human birth defects, associated with lenalidomide and pomalidomide, and they are contraindicated for use in pregnancy. Refer to the respective product full prescribing information for requirements regarding contraception and the prohibitions against blood and/or sperm donation due to presence and transmission in blood and/or semen and for additional information.

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
HOW EMPLICITI IS SUPPLIED

Supply

EMPLICITI is supplied in 300 and 400 mg single-dose vials. EMPLICITI is a sterile, nonpyrogenic, preservative-free lyophilized powder that is white to off-white, whole or fragmented cake that is provided in 2 strengths.

Carton contents
300 mg single-dose vial for IV infusion
10-digit-NDC  11-digit-NDC
0003-2291-11  00003-2291-11

Carton contents
400 mg single-dose vial for IV infusion
10-digit-NDC  11-digit-NDC
0003-4522-11  00003-4522-11

SELECTED IMPORTANT SAFETY INFORMATION

Adverse Reactions

- ELOQUENT-2 trial:
  - Serious adverse reactions were 65% (ERd) and 57% (Rd). The most frequent serious adverse reactions in the ERd arm compared to the Rd arm were: pneumonia (15%, 11%), pyrexia (7%, 5%), respiratory tract infection (3.1%, 1.3%), anemia (2.8%, 1.9%), pulmonary embolism (3.1%, 2.5%), and acute renal failure (2.5%, 1.9%).
  - The most common adverse reactions in ERd and Rd, respectively (≥20%) were fatigue (62%, 52%), diarrhea (47%, 36%), pyrexia (37%, 25%), constipation (36%, 27%), cough (34%, 19%), peripheral neuropathy (27%, 21%), nasopharyngitis (25%, 19%), upper respiratory tract infection (23%, 17%), decreased appetite (21%, 13%), and pneumonia (20%, 14%).

- ELOQUENT-3 trial:
  - Serious adverse reactions were 22% (EPd) and 15% (Pd). The most frequent serious adverse reactions in the EPd arm compared to the Pd arm were: pneumonia (13%, 11%) and respiratory tract infection (7%, 3.6%).
  - The most common adverse reactions in EPd arm (≥20% EPd) and Pd, respectively, were constipation (22%, 11%) and hyperglycemia (20%, 15%).

Please see additional Important Safety Information throughout. 
Click here for full Prescribing Information.
HOW EMPLICITI IS STORED

Storage of reconstituted solution
If not used immediately, the infusion solution may be stored under refrigeration conditions: 2°C to 8°C (36°F–46°F) and protected from light for up to 24 hours
• A maximum of 8 hours of the total 24 hours can be at room temperature, 20°C to 25°C (68°F–77°F), and in room light

Storage of non-reconstituted vials

Refrigerate at 2°C to 8°C (36°F–46°F)
Protect EMPLICITI from light by storing in the original package until time of use
Do not freeze
Do not shake

Please see additional Important Safety Information throughout. Click here for full Prescribing Information.
Because dosing for EMPLICITI is weight-based, the dose of EMPLICITI will vary by patient and may be provided through a combination of vial sizes. EMPLICITI is supplied in 300 and 400 mg single-dose vials.

Determining your order for EMPLICITI

1. Calculate total dose in mg needed: \[ \text{weight in kg} \times \text{dose in mg/kg} = \text{total dose in mg} \]

2. Determine quantity of single-dose vials needed based on total dose (see examples in table below)

### EXAMPLES OF VIAL QUANTITIES NEEDED FOR WEIGHT-BASED DOSING OF EMPLICITI

<table>
<thead>
<tr>
<th>10 mg/kg dose</th>
<th>weight</th>
<th>20 mg/kg dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vials*</td>
<td>Total dose (mg)</td>
<td>Patient wt. (kg)</td>
</tr>
<tr>
<td>300 x2</td>
<td>410–600</td>
<td>41–60</td>
</tr>
<tr>
<td>300 + 400 x2</td>
<td>610–700</td>
<td>61–70</td>
</tr>
<tr>
<td>400 x2</td>
<td>710–800</td>
<td>71–80</td>
</tr>
<tr>
<td>300 x3</td>
<td>810–900</td>
<td>81–90</td>
</tr>
<tr>
<td>300 x2 + 400</td>
<td>910–1000</td>
<td>91–100</td>
</tr>
<tr>
<td>300 + 400 x2</td>
<td>1010–1100</td>
<td>101–110</td>
</tr>
<tr>
<td>400 x3</td>
<td>1110–1200</td>
<td>111–120</td>
</tr>
<tr>
<td>300 x3 + 400</td>
<td>1210–1300</td>
<td>121–130</td>
</tr>
<tr>
<td>300 x2 + 400 x2</td>
<td>1310–1400</td>
<td>131–140</td>
</tr>
</tbody>
</table>

*Depending on the weight-based dose, the full amount in the vials may not be used.
# DISTRIBUTION OF EMPLICITI

## PHYSICIAN OFFICES

<table>
<thead>
<tr>
<th>Specialty Distributor</th>
<th>Phone Number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardinal Health Specialty Pharmaceutical Distribution</td>
<td>1-866-677-4844 (24-hour emergency on-call)</td>
<td><a href="https://specialtyonline.cardinalhealth.com">https://specialtyonline.cardinalhealth.com</a></td>
</tr>
<tr>
<td>CuraScript SD Specialty Distribution</td>
<td>1-877-599-7748 Monday-Friday, 8:30 AM - 7 PM ET</td>
<td><a href="https://www.curascriptsd.com">https://www.curascriptsd.com</a></td>
</tr>
<tr>
<td>McKesson Specialty Health</td>
<td>1-800-482-6700 Monday-Friday, 7 AM - 7 PM CT</td>
<td><a href="https://mscs.mckesson.com">https://mscs.mckesson.com</a></td>
</tr>
<tr>
<td>Oncology Supply</td>
<td>1-800-633-7555 Monday-Friday, 8 AM - 7 PM CT</td>
<td><a href="https://www.oncologysupply.com">https://www.oncologysupply.com</a></td>
</tr>
</tbody>
</table>

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain EMPLICITI from the distributors listed below.

## HOSPITALS AND INFUSION CENTERS

<table>
<thead>
<tr>
<th>Specialty Distributor</th>
<th>Phone Number</th>
<th>Fax Number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASD Healthcare</td>
<td>1-800-766-6273 Monday-Thursday, 7 AM - 6:30 PM CT; Friday 7 AM - 6 PM CT</td>
<td>1-800-547-9413</td>
<td><a href="https://www.asdhealthcare.com">https://www.asdhealthcare.com</a></td>
</tr>
<tr>
<td>Cardinal Health Specialty Pharmaceutical Distribution</td>
<td>1-866-677-4844 (24-hour emergency on-call)</td>
<td>1-888-345-4916</td>
<td><a href="https://OrderExpress.cardinalhealth.com">https://OrderExpress.cardinalhealth.com</a></td>
</tr>
<tr>
<td>DMS Pharmaceutical Group, Inc.</td>
<td>1-877-788-1100 Monday-Friday, 8 AM - 6 PM CT</td>
<td>1-847-518-1105</td>
<td><a href="http://www.dmspharma.com">www.dmspharma.com</a></td>
</tr>
<tr>
<td>McKesson Plasma and Biologics</td>
<td>1-877-625-2566 Monday-Friday, 8 AM - 6:30 PM CT</td>
<td>1-888-752-7626</td>
<td><a href="https://connect.mckesson.com">https://connect.mckesson.com</a></td>
</tr>
</tbody>
</table>

The distribution program for EMPLICITI includes extended payment terms to Bristol Myers Squibb’s authorized distributors. Healthcare providers and institutions should contact their distributor to understand specific payment terms that may be available to them from their distributor.

Please see Important Safety Information throughout. Click here for full Prescribing Information.
INFUSED PRODUCT RETURN POLICY

Usable and unopened
If product is usable and unopened and the return is due to:
• A patient’s unavailability for treatment with EMPLICITI due to one of the following:
  – Patient refusal
  – Adverse event
  – Patient illness or death
  – Patient ineligibility
• Ordering error

Please contact your specialty distributor directly for assistance.

Not usable
If product is not usable and the return is due to:
• Compromised refrigeration
• Damage (for example, dropped or mishandled vial)
• Opened product (for example, incorrect preparation or mixed prior to patient unavailability)

Please contact Bristol Myers Squibb Customer Service by either:

Emailing CustomerServiceOperations@BMS.com

or

Calling 1-800-631-5244, 9 AM to 5 PM ET, Monday–Friday

Request must be made within 90 days of invoice date. Be prepared to provide date and reason for return, number of vials affected, invoice number, and date.

Eligibility
• Dispensing customers: physicians, infusion centers, hospitals, specialty pharmacies, other healthcare providers
• $400,000 credit cap per rolling year will be applied per customer across all Bristol Myers Squibb products that are covered by the policy

Product disposal
• If a product is damaged or the vial is leaking, please properly dispose of product according to institution guidelines. Bristol Myers Squibb cannot pick up or dispose of the damaged product

Please see Important Safety Information throughout. Click here for full Prescribing Information.
Return policy steps for product that is not usable

Bristol Myers Squibb offers an EMPLICITI Product Return Policy that credits customers at the Wholesale List Price or direct contract price at the time of purchase in the event of loss occurring within 90 days of the invoice date.

To request a return, contact Bristol Myers Squibb Customer Service by:

Emailing CustomerServiceOperations@BMS.com
Visiting us at www.BMSInfusedProductReturns.com

or

Calling 1-800-631-5244, 9 AM to 5 PM ET, Monday–Friday

Representatives are available to assist you by:

• Providing a request form and instructions
• Clarifying policy or required information
• Helping with form submission

Within 48 hours of form submission, you will receive an email with a return request reference number or an email notifying you that further documentation is required

Within 1 week from submission, you will receive an approval or denial notice by email. If approved, product pick-up will be initiated

After product has been received by Bristol Myers Squibb, Bristol Myers Squibb will provide credit to the corresponding wholesaler/distributor within 30 days and will email a credit reference number

• Distributor issues credit to dispensing customer

Please see Important Safety Information throughout.
Click here for full Prescribing Information.
For physicians and patients who have chosen a BMS medication:

**Patient Access, Reimbursement, and Co-Pay Support**

Available through:

- Call Bristol Myers Squibb Access Support® at 1-800-861-0048
  8 AM to 8 PM ET, Monday–Friday to speak with a regionally assigned specialist

- Visit [www.BMSAccessSupport.com](http://www.BMSAccessSupport.com) for information and resources, including the enrollment form, to help you and your patients with access to Bristol Myers Squibb oncology products

---

**Three Simple Ways to Get Support**

- Contact your Access & Reimbursement Manager for assistance and to schedule an office visit

- Call Bristol Myers Squibb Access Support® at 1-800-861-0048
  8 AM to 8 PM ET, Monday–Friday to speak with a regionally assigned specialist

- Visit [www.BMSAccessSupport.com](http://www.BMSAccessSupport.com) for information and resources, including the enrollment form, to help you and your patients with access to Bristol Myers Squibb oncology products

---

**BMS Access Support is committed to providing access and reimbursement support, including co-pay assistance for eligible commercially insured patients**

---

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
RESPONDING TO YOUR NEEDS IN 24 HOURS OR LESS

Bristol-Myers Squibb remains committed to helping you and your patients throughout treatment with EMPLICITI.

EMPLICITI patient support at EmplicitiHCP.com
- Learn about available patient support
- Download educational materials for your patients
- Contact a Care Navigator

Meet with an EMPLICITI representative
- Call to schedule a visit from one of our EMPLICITI representatives for product information

1-844-EMPLICITI (1-844-367-5424) for live support and assistance
Responses provided during business hours, 8:00 AM to 8:00 PM ET, Monday–Friday

Please see Important Safety Information throughout. Click here for full Prescribing Information.


EMPLICITI and the related logo are trademarks and Access Support and the related logo are registered trademarks of Bristol-Myers Squibb Company. © 2020 Bristol-Myers Squibb Company. All rights reserved. US-EMP-20-0010 03/20